| Schedule of net revenues by product |
The following tables detail AbbVie's worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2022 | | 2021 | | 2020 | | Immunology | | | | | | | Humira | United States | $ | 18,619 | | | $ | 17,330 | | | $ | 16,112 | | | International | 2,618 | | | 3,364 | | | 3,720 | | | Total | $ | 21,237 | | | $ | 20,694 | | | $ | 19,832 | | | Skyrizi | United States | $ | 4,484 | | | $ | 2,486 | | | $ | 1,385 | | | International | 681 | | | 453 | | | 205 | | | Total | $ | 5,165 | | | $ | 2,939 | | | $ | 1,590 | | | Rinvoq | United States | $ | 1,794 | | | $ | 1,271 | | | $ | 653 | | | International | 728 | | | 380 | | | 78 | | | Total | $ | 2,522 | | | $ | 1,651 | | | $ | 731 | | | Hematologic Oncology | | | | | | | Imbruvica | United States | $ | 3,426 | | | $ | 4,321 | | | $ | 4,305 | | | Collaboration revenues | 1,142 | | | 1,087 | | | 1,009 | | | Total | $ | 4,568 | | | $ | 5,408 | | | $ | 5,314 | | | Venclexta | United States | $ | 1,009 | | | $ | 934 | | | $ | 804 | | | International | 1,000 | | | 886 | | | 533 | | | Total | $ | 2,009 | | | $ | 1,820 | | | $ | 1,337 | | | Aesthetics | | | | | | Botox Cosmetic (a) | United States | $ | 1,654 | | | $ | 1,424 | | | $ | 687 | | | International | 961 | | | 808 | | | 425 | | | Total | $ | 2,615 | | | $ | 2,232 | | | $ | 1,112 | | Juvederm Collection (a) | United States | $ | 548 | | | $ | 658 | | | $ | 318 | | | International | 880 | | | 877 | | | 400 | | | Total | $ | 1,428 | | | $ | 1,535 | | | $ | 718 | | Other Aesthetics (a) | United States | $ | 1,122 | | | $ | 1,268 | | | $ | 666 | | | International | 168 | | | 198 | | | 94 | | | Total | $ | 1,290 | | | $ | 1,466 | | | $ | 760 | | | Neuroscience | | | | | | Botox Therapeutic (a) | United States | $ | 2,255 | | | $ | 2,012 | | | $ | 1,155 | | | International | 464 | | | 439 | | | 232 | | | Total | $ | 2,719 | | | $ | 2,451 | | | $ | 1,387 | | Vraylar (a) | United States | $ | 2,037 | | | $ | 1,728 | | | $ | 951 | | | International | 1 | | | — | | | — | | | Total | $ | 2,038 | | | $ | 1,728 | | | $ | 951 | | | Duodopa | United States | $ | 95 | | | $ | 102 | | | $ | 103 | | | International | 363 | | | 409 | | | 391 | | | Total | $ | 458 | | | $ | 511 | | | $ | 494 | | Ubrelvy (a) | United States | $ | 680 | | | $ | 552 | | | $ | 125 | | | Qulipta | United States | $ | 158 | | | $ | — | | | $ | — | | | | | | | | | | | | | | | | Other Neuroscience (a) | United States | $ | 456 | | | $ | 667 | | | $ | 528 | | | International | 19 | | | 18 | | | 11 | | | Total | $ | 475 | | | $ | 685 | | | $ | 539 | |
| | | | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2022 | | 2021 | | 2020 | | Eye Care | | | | | | Lumigan/Ganfort (a) | United States | $ | 242 | | | $ | 273 | | | $ | 165 | | | International | 272 | | | 306 | | | 213 | | | Total | $ | 514 | | | $ | 579 | | | $ | 378 | | Alphagan/Combigan (a) | United States | $ | 202 | | | $ | 373 | | | $ | 223 | | | International | 144 | | | 156 | | | 103 | | | Total | $ | 346 | | | $ | 529 | | | $ | 326 | | Restasis (a) | United States | $ | 621 | | | $ | 1,234 | | | $ | 755 | | | International | 45 | | | 56 | | | 32 | | | Total | $ | 666 | | | $ | 1,290 | | | $ | 787 | | Other Eye Care (a) | United States | $ | 538 | | | $ | 523 | | | $ | 305 | | | International | 637 | | | 646 | | | 388 | | | Total | $ | 1,175 | | | $ | 1,169 | | | $ | 693 | | | Other Key Products | | | | | | | Mavyret | United States | $ | 755 | | | $ | 754 | | | $ | 785 | | | International | 786 | | | 956 | | | 1,045 | | | Total | $ | 1,541 | | | $ | 1,710 | | | $ | 1,830 | | | Creon | United States | $ | 1,278 | | | $ | 1,191 | | | $ | 1,114 | | Linzess/Constella (a) | United States | $ | 1,003 | | | $ | 1,006 | | | $ | 649 | | | International | 32 | | | 32 | | | 18 | | | Total | $ | 1,035 | | | $ | 1,038 | | | $ | 667 | | | All other | | $ | 4,137 | | | $ | 5,019 | | | $ | 5,119 | | | Total net revenues | $ | 58,054 | | | $ | 56,197 | | | $ | 45,804 | |
(a)Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.
|
| Schedule of net revenues to external customers by geographic area |
Net revenues to external customers by geographic area, based on product shipment destination, were as follows: | | | | | | | | | | | | | | | | | | | years ended December 31 (in millions) | 2022 | | 2021 | | 2020 | | United States | $ | 45,713 | | | $ | 43,510 | | | $ | 34,879 | | | Germany | 1,340 | | | 1,223 | | | 1,049 | | | Canada | 1,159 | | | 1,397 | | | 1,159 | | | Japan | 956 | | | 1,090 | | | 1,198 | | | China | 912 | | | 857 | | | 471 | | | France | 787 | | | 936 | | | 797 | | | Australia | 508 | | | 533 | | | 527 | | | Spain | 506 | | | 519 | | | 453 | | | United Kingdom | 462 | | | 497 | | | 509 | | | Italy | 444 | | | 506 | | | 379 | | | Brazil | 430 | | | 368 | | | 406 | | | All other countries | 4,837 | | | 4,761 | | | 3,977 | | | Total net revenues | $ | 58,054 | | | $ | 56,197 | | | $ | 45,804 | |
|